Pharmerica Corporation Company Profile (NYSE:PMC)

About Pharmerica Corporation (NYSE:PMC)

Pharmerica Corporation logoPharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals and specialty infusion services to patients outside a hospital setting, and offers the national oncology pharmacy in the United States. Its segments include institutional pharmacy, which provides pharmacy products and services to residents and patients in skilled nursing facilities, nursing centers, assisted living facilities, hospitals and other long-term alternative care settings; specialty infusion services, which provides specialty infusion services focused on providing pharmaceutical products and clinical services to patients in client facilities, hospice and outside of hospital or nursing home settings, and specialty oncology pharmacy, which provides dispensing of oncology drugs, care management and other related services to patients, oncology practices and hospitals.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Retailers
  • Sub-Industry: Health Care Distributors
  • Symbol: NYSE:PMC
  • CUSIP: 71714F10
  • Web:
  • Market Cap: $907.18 million
  • Outstanding Shares: 31,121,000
Average Prices:
  • 50 Day Moving Avg: $28.94
  • 200 Day Moving Avg: $25.67
  • 52 Week Range: $19.20 - $29.40
  • Trailing P/E Ratio: 39.30
  • Foreward P/E Ratio: 13.31
  • P/E Growth: 1.54
Sales & Book Value:
  • Annual Revenue: $2.21 billion
  • Price / Sales: 0.41
  • Book Value: $17.89 per share
  • Price / Book: 1.63
  • EBIDTA: $133 million
  • Net Margins: 1.05%
  • Return on Equity: 10.94%
  • Return on Assets: 4.84%
  • Debt-to-Equity Ratio: 0.75%
  • Current Ratio: 2.57%
  • Quick Ratio: 1.79%
  • Average Volume: 463,161 shs.
  • Beta: 0.84
  • Short Ratio: 3.94

Frequently Asked Questions for Pharmerica Corporation (NYSE:PMC)

What is Pharmerica Corporation's stock symbol?

Pharmerica Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "PMC."

How were Pharmerica Corporation's earnings last quarter?

Pharmerica Corporation (NYSE:PMC) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported $0.47 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.47. The business had revenue of $592 million for the quarter, compared to the consensus estimate of $592.96 million. Pharmerica Corporation had a return on equity of 10.94% and a net margin of 1.05%. The firm's revenue was up 13.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.47 EPS. View Pharmerica Corporation's Earnings History.

When will Pharmerica Corporation make its next earnings announcement?

Pharmerica Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Pharmerica Corporation.

Where is Pharmerica Corporation's stock going? Where will Pharmerica Corporation's stock price be in 2017?

3 brokers have issued 1 year price objectives for Pharmerica Corporation's shares. Their forecasts range from $29.25 to $29.25. On average, they expect Pharmerica Corporation's share price to reach $29.25 in the next year. View Analyst Ratings for Pharmerica Corporation.

Are investors shorting Pharmerica Corporation?

Pharmerica Corporation saw a increase in short interest in the month of August. As of August 15th, there was short interest totalling 1,211,533 shares, an increase of 58.0% from the July 31st total of 766,695 shares. Based on an average trading volume of 1,419,804 shares, the short-interest ratio is currently 0.9 days. Currently, 4.1% of the shares of the company are short sold.

Who are some of Pharmerica Corporation's key competitors?

Who are Pharmerica Corporation's key executives?

Pharmerica Corporation's management team includes the folowing people:

  • Geoffrey G. Meyers, Independent Chairman of the Board
  • Gregory S. Weishar, Chief Executive Officer, Director
  • Suresh Vishnubhatla, Executive Vice President - Long-term Care Operations
  • Berard E. Tomassetti, Senior Vice President, Chief Accounting Officer
  • Thomas A. Caneris, Senior Vice President, General Counsel, Secretary
  • Robert A. McKay, Senior Vice President - Purchasing and Trade Relations
  • Frank E. Collins Esq., Independent Director
  • W. Robert Robert Dahl Jr., Independent Director
  • Marjorie W. Dorr, Independent Director
  • Patrick G. LePore, Independent Director

Who owns Pharmerica Corporation stock?

Pharmerica Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.58%), Dimensional Fund Advisors LP (8.41%), Vanguard Group Inc. (5.30%), Boston Partners (4.43%), Victory Capital Management Inc. (4.16%) and FMR LLC (3.68%). Company insiders that own Pharmerica Corporation stock include Mark Lindemoen and Robert A Mckay. View Institutional Ownership Trends for Pharmerica Corporation.

Who sold Pharmerica Corporation stock? Who is selling Pharmerica Corporation stock?

Pharmerica Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, American Century Companies Inc., Ameriprise Financial Inc., Systematic Financial Management LP, Prudential PLC, Citadel Advisors LLC, BlackRock Inc. and Prudential Financial Inc.. View Insider Buying and Selling for Pharmerica Corporation.

Who bought Pharmerica Corporation stock? Who is buying Pharmerica Corporation stock?

Pharmerica Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Royce & Associates LP, Victory Capital Management Inc., Boston Partners, Vanguard Group Inc., Chicago Equity Partners LLC, Brandywine Global Investment Management LLC, Algert Global LLC and Northern Trust Corp. View Insider Buying and Selling for Pharmerica Corporation.

How do I buy Pharmerica Corporation stock?

Shares of Pharmerica Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pharmerica Corporation's stock price today?

One share of Pharmerica Corporation stock can currently be purchased for approximately $29.15.

MarketBeat Community Rating for Pharmerica Corporation (NYSE PMC)
Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  283
MarketBeat's community ratings are surveys of what our community members think about Pharmerica Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pharmerica Corporation (NYSE:PMC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $29.25 (0.34% upside)

Analysts' Ratings History for Pharmerica Corporation (NYSE:PMC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/9/2017Barrington ResearchDowngradeOutperform -> UnderperformLowView Rating Details
8/8/2017KeyCorpDowngradeOverweightLowView Rating Details
8/4/2017Credit Suisse GroupDowngradeOutperform -> Neutral$29.00 -> $29.25LowView Rating Details
6/7/2016Bank of America CorporationInitiated CoverageBuy$32.00N/AView Rating Details
2/29/2016Barclays PLCLower Price TargetUnderweight$27.00 -> $22.00N/AView Rating Details
12/30/2015Cowen and CompanyReiterated RatingBuy$39.00 -> $41.00N/AView Rating Details
(Data available from 9/20/2015 forward)


Earnings History for Pharmerica Corporation (NYSE:PMC)
Earnings by Quarter for Pharmerica Corporation (NYSE:PMC)
Earnings History by Quarter for Pharmerica Corporation (NYSE PMC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017$0.49N/AView Earnings Details
8/2/2017Q2 2017$0.47$0.47$592.96 million$592.00 millionViewN/AView Earnings Details
5/10/2017Q1 2017$0.40$0.42$536.85 million$566.80 millionViewN/AView Earnings Details
2/24/2017Q416$0.51$0.58$525.22 million$534.40 millionViewListenView Earnings Details
11/9/2016Q316$0.51$0.44$530.01 million$512.60 millionViewListenView Earnings Details
8/9/2016Q216$0.47$0.47$508.31 million$519.60 millionViewListenView Earnings Details
5/6/2016Q116$0.43$0.45$509.45 million$524.50 millionViewListenView Earnings Details
2/26/2016Q415$0.41$0.45$506.40 million$520.60 millionViewListenView Earnings Details
11/6/2015Q315$0.36$0.39$480.35 million$498.80 millionViewListenView Earnings Details
8/7/2015Q215$0.33$0.37$491.66 million$497.50 millionViewListenView Earnings Details
5/7/2015Q115$0.43$0.48$500.95 million$511.60 millionViewListenView Earnings Details
3/2/2015Q414$0.43$0.45$491.99 million$523.50 millionViewListenView Earnings Details
11/6/2014Q314$0.40$0.45$439.63 million$470.20 millionViewListenView Earnings Details
8/5/2014Q214$0.36$0.40$432.70 million$448.60 millionViewListenView Earnings Details
5/1/2014Q114$0.33$0.37$417.76 million$452.20 millionViewListenView Earnings Details
2/28/2014Q413$0.38$0.44$421.16 million$433.20 millionViewListenView Earnings Details
11/5/2013Q313$0.32$0.49$398.02 million$442.00 millionViewListenView Earnings Details
8/2/2013Q2 2013$0.34$0.44$414.15 million$458.50 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.34$0.46$435.10 million$439.80 millionViewListenView Earnings Details
2/7/2013Q4 2012$0.29$0.12$432.43 million$433.20 millionViewListenView Earnings Details
11/1/2012Q312$0.30$0.33$446.36 million$442.00 millionViewN/AView Earnings Details
8/2/2012$0.30$0.32ViewN/AView Earnings Details
5/2/2012$0.27$0.30ViewN/AView Earnings Details
2/9/2012$0.21$0.27ViewN/AView Earnings Details
11/3/2011$0.20$0.31ViewN/AView Earnings Details
8/4/2011$0.20$0.32ViewN/AView Earnings Details
5/5/2011$0.20$0.21ViewN/AView Earnings Details
2/24/2011$0.17$0.16ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pharmerica Corporation (NYSE:PMC)
2017 EPS Consensus Estimate: $1.88
2018 EPS Consensus Estimate: $2.12
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.40$0.40$0.40
Q2 20172$0.46$0.47$0.47
Q3 20172$0.49$0.50$0.50
Q4 20172$0.51$0.53$0.52
Q1 20181$0.46$0.46$0.46
Q2 20181$0.52$0.52$0.52
Q3 20181$0.55$0.55$0.55
Q4 20181$0.59$0.59$0.59
(Data provided by Zacks Investment Research)


Dividend History for Pharmerica Corporation (NYSE:PMC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Pharmerica Corporation (NYSE:PMC)
Insider Ownership Percentage: 5.21%
Institutional Ownership Percentage: 92.15%
Insider Trades by Quarter for Pharmerica Corporation (NYSE:PMC)
Institutional Ownership by Quarter for Pharmerica Corporation (NYSE:PMC)
Insider Trades by Quarter for Pharmerica Corporation (NYSE:PMC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2015Robert A MckaySVPSell2,993$34.42$103,019.06View SEC Filing  
11/11/2015Mark LindemoenSVPSell3,790$34.71$131,550.90View SEC Filing  
6/16/2015Robert A MckaySVPSell7,000$32.75$229,250.00View SEC Filing  
6/3/2015Gregory S WeisharCEOSell104,150$32.63$3,398,414.50View SEC Filing  
6/1/2015Mark LindemoenSVPSell4,500$33.27$149,715.00View SEC Filing  
3/12/2015Berard TomassettiCAOSell3,344$26.44$88,415.36View SEC Filing  
3/12/2015Thomas A CanerisSVPSell7,495$26.52$198,767.40View SEC Filing  
3/6/2015Robert A MckaySVPSell20,000$26.74$534,800.00View SEC Filing  
8/8/2014Robert A OakleyDirectorSell8,399$26.55$222,993.45View SEC Filing  
5/13/2014Thomas CanerisSVPSell12,192$28.60$348,691.20View SEC Filing  
3/14/2014Gregory WeisharCEOSell60,000$26.27$1,576,200.00View SEC Filing  
3/13/2014Robert MckaySVPSell18,646$26.08$486,287.68View SEC Filing  
3/12/2014Berard TomassettiCAOSell3,812$25.22$96,138.64View SEC Filing  
3/6/2014Thomas CanerisSVPSell14,357$25.60$367,539.20View SEC Filing  
11/22/2013Thomas GerrityDirectorSell3,271$20.56$67,251.76View SEC Filing  
11/15/2013Berard TomassettiCAOSell4,097$20.55$84,193.35View SEC Filing  
5/30/2013Berard TomassettiCAOSell9,724$15.68$152,472.32View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Pharmerica Corporation (NYSE:PMC)
Latest Headlines for Pharmerica Corporation (NYSE:PMC)
DateHeadline logoPharMerica Corporation -- Moody's assigns B2 CFR to PharMerica Corporation; outlook stable - September 13 at 7:54 AM logo$596.80 Million in Sales Expected for Pharmerica Corporation (PMC) This Quarter - September 4 at 4:52 AM logoZacks: Analysts Expect Pharmerica Corporation (PMC) Will Announce Earnings of $0.50 Per Share - September 2 at 4:10 PM logoPharmerica Corporation (PMC) Sees Significant Growth in Short Interest - August 31 at 1:46 AM logoPharmerica Corporation (PMC) Given Average Recommendation of "Hold" by Brokerages - August 28 at 2:36 AM logoComparing Pharmerica Corporation (PMC) and MWI Veterinary Supply (MWIV) - August 22 at 8:30 AM logoAnalyzing Pharmerica Corporation (PMC) & MWI Veterinary Supply (MWIV) - August 20 at 4:22 AM logoMWI Veterinary Supply (MWIV) and Pharmerica Corporation (PMC) Financial Review - August 14 at 12:28 AM logoHead to Head Review: Pharmerica Corporation (NYSE:PMC) & Cardinal Health (CAH) - August 10 at 10:24 PM logoPharmerica Corporation (NYSE:PMC) Lowered to "Overweight" at KeyCorp - August 8 at 8:56 PM logoResearch Analysts Offer Predictions for Pharmerica Corporation's Q4 2018 Earnings (PMC) - August 7 at 9:30 AM logoPharmerica Corporation (PMC) Cut to "Neutral" at Credit Suisse Group - August 6 at 9:40 PM logoPharmerica Corporation to Post Q3 2017 Earnings of $0.50 Per Share, Barrington Research Forecasts (NYSE:PMC) - August 4 at 7:22 AM logoPharMerica Corp. breached its 50 day moving average in a Bullish Manner : PMC-US : August 3, 2017 - August 4 at 7:05 AM logoHealthcare Q2 Earnings to Watch Out on Aug 4: WCG & PMC - August 4 at 7:05 AM logoPHARMERICA CORPORATION SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition by KKR & Co. L.P. Unit May be Unfair to Shareholders - August 4 at 7:05 AM logoPHARMERICA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of PharMerica Corporation - August 4 at 7:05 AM logoPHARMERICA CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout - August 4 at 7:05 AM logoBragar Eagel & Squire, P.C. Is Investigating the Board of Directors of PharMerica Corporation (PMC) on Behalf of Stockholders and Encourages Investors to Contact the Firm - August 4 at 7:05 AM logoPharMerica Corp.: Strong price momentum but will it sustain? - August 4 at 7:05 AM logoPharmerica Corporation (PMC) Receives Average Rating of "Hold" from Brokerages - August 4 at 12:18 AM logoPharmerica Corporation (NYSE:PMC) Rating Reiterated by UBS AG - August 3 at 10:28 PM logoPharmerica Corporation (PMC) Forecasted to Post FY2017 Earnings of $1.91 Per Share - August 3 at 9:50 AM logoPharMerica To Be Acquired By KKR In Approximately $1.4 Bln Deal - Quick Facts - August 3 at 7:01 AM logoKKR to take PharMerica private in $1.4 billion deal - August 3 at 7:01 AM logoPharMerica (PMC) Alert: J&W Investigates Proposed Sale of PharMerica Corporation; Is $29.25 a Fair Price? - August 3 at 7:01 AM logoWeissLaw LLP: PharMerica Corp. Acquisition May Not Be in the Best Interests of PMC Shareholders - August 3 at 7:00 AM logoPharmerica (PMC) to Be Acquired by KKR for $29.25 per Share - August 3 at 7:00 AM logoThe Law Offices of Vincent Wong Notifies Investors of an Investigation into Possible Breaches of Fiduciary Duty by the Board of PharMerica Corporation in Connection with the Sale of the Company to KR and Walgreens Boots Alliance, Inc. - August 3 at 7:00 AM logoRowley Law PLLC is Investigating PharMerica Corporation and its Board of Directors for Potential Breaches of Fiduciary Duty - August 3 at 7:00 AM logoPharMerica meets 2Q profit forecasts - August 3 at 7:00 AM logoWhy PharMerica Stock Is Soaring Today - August 2 at 1:53 PM logoKKR-controlled company to acquire PharMerica for $1.4B - August 2 at 8:43 AM logoPharMerica Corp. – Value Analysis (NYSE:PMC) : August 1, 2017 - August 1 at 9:32 PM logo$592.15 Million in Sales Expected for Pharmerica Corporation (PMC) This Quarter - July 29 at 7:20 AM logoPharmerica Corporation (NYSE:PMC) to Release Earnings on Friday - July 28 at 1:30 AM logoPharMerica Corporation Announces Second Quarter 2017 Earnings Call and Webcast - July 21 at 6:16 AM logoPharMerica Corp. breached its 50 day moving average in a Bearish Manner : PMC-US : July 19, 2017 - July 19 at 3:15 PM logoHead to Head Analysis: Pharmerica Corporation (PMC) vs. CVS Health Corporation (CVS) - July 15 at 12:28 AM logoFinancial Contrast: CVS Health Corporation (CVS) vs. Pharmerica Corporation (NYSE:PMC) - July 10 at 12:14 AM logoHead to Head Comparison: AmerisourceBergen Corporation (Holding Co) (ABC) & Pharmerica Corporation (PMC) - July 8 at 12:16 AM logoPharmerica Corporation (PMC) Expected to Announce Earnings of $0.47 Per Share - July 3 at 8:28 PM logoFinancial Review: Pharmerica Corporation (PMC) vs. Prestige Brand Holdings (PBH) - June 27 at 2:39 PM logoETFs with exposure to PharMerica Corp. : June 26, 2017 - June 27 at 7:21 AM logoPharmerica Corporation (PMC) Cut to "Hold" at Zacks Investment Research - June 24 at 10:40 AM logoPharmerica Corporation (PMC) Raised to Buy at Zacks Investment Research - June 24 at 7:06 AM logoPharMerica shrinks board of directors - June 21 at 1:53 AM logo$592.15 Million in Sales Expected for PharMerica Co. (PMC) This Quarter - June 9 at 1:00 PM logoETFs with exposure to PharMerica Corp. : June 8, 2017 - June 8 at 8:08 PM logo$0.47 Earnings Per Share Expected for PharMerica Co. (PMC) This Quarter - June 7 at 6:30 PM



Pharmerica Corporation (PMC) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff